Zobrazeno 1 - 10
of 965
pro vyhledávání: '"F, Follath"'
Publikováno v:
Swiss Medical Weekly, Vol 140, Iss 4546 (2010)
BACKGROUND: Hospitalised patients with acute heart failure (AHF) suffer from a high morbidity and mortality, which might, at least partly, be influenced by concomitant infections. The aim of this observational study was to investigate the impact of i
Externí odkaz:
https://doaj.org/article/9f270f75c17a42aab2238d5839de1388
A narrow therapeutic margin and poor predictability of plasma concentrations are the main reasons for drug level monitoring during aminoglycoside treatment. Gentamicin, tobramycin, amikacin and netilmicin can now be accurately and rapidly measured by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22ab15283ad0ccfcfeeda56149adbcd4
http://doc.rero.ch/record/301650/files/8-suppl_A-37.pdf
http://doc.rero.ch/record/301650/files/8-suppl_A-37.pdf
Autor:
F. Follath
Trimethoprim (TMP), sulfamethoxazole (SMZ) and sulfadiazine (SDZ) are characterized by elimination half-lives of 9 to 15 h. Effective serum concentrations can therefore be maintained by twice daily administration, but without a loading dose steady st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3eb46786680226205d4b36aa34d2793
http://doc.rero.ch/record/295417/files/5-Supplement_B-97.pdf
http://doc.rero.ch/record/295417/files/5-Supplement_B-97.pdf
Autor:
F. Follath
Publikováno v:
Fundamental & Clinical Pharmacology. 23:669-673
The fundamental values in medical ethics include the following aspects of professional conduct: (i) actions in the best interest of patients; (ii) first, do no harm; (iii) patients' right to refuse or choose treatments; (iv) fairness and equality in
Autor:
Giovanni G. Camici, Anna Bogdanova, Simon F. Stämpfli, Felix C. Tanner, Huy Riem Ha, Alexander Akhmedov, Thomas F. Lüscher, F. Follath, Alexander Breitenstein
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology. 28:2231-2238
Background— In patients with coronary artery disease and reduced ejection fraction, amiodarone reduces mortality by decreasing sudden death. Because the latter may be triggered by coronary artery thrombosis as much as ventricular arrhythmias, amiod
Autor:
M. Pfisterer, R. Handschin, D. Hack, R. Zaker, Thilo Burkard, U. Pittl, H. P. Brunner-La Rocca, O. Pfister, F. Follath, H. Rickli
Publikováno v:
QJM: An International Journal of Medicine, 107(2), 131-138. Oxford University Press
Background and aims: Inflammation is part of the pathophysiology of congestive heart failure (CHF). However, little is known about the impact of the presence of systemic inflammatory disease (SID), defined as inflammatory syndrome with constitutional
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::966718aa98c400ab382da5f8a6d58c2e
https://cris.maastrichtuniversity.nl/en/publications/8b18dd43-872b-4052-8a39-0146d5bb0fbc
https://cris.maastrichtuniversity.nl/en/publications/8b18dd43-872b-4052-8a39-0146d5bb0fbc
Publikováno v:
Annals of Oncology. 12:963-966
Summary Background Acute cardiotoxicity due to anthracyclines is a rare, but life-threatening event. Interindividual sensitivity to anthracyclines is highly variable and cannot be predicted for the individual patient. Patients and methods This is a r
Publikováno v:
Xenobiotica. 31:239-248
1. Amiodarone (AMI) is a potent anti-arrhythmic drug and mono-N-desethylamiodarone (MDEA) is its only known metabolite. It was found recently that in rabbit liver microsomes MDEA was biotransformed to n-3-hydroxybutyl-MDEA (3OH-MDEA). 2. In liver mic
Publikováno v:
Intensivmedizin und Notfallmedizin. 37:S063-S070